RainDance Technologies Names Fritz Eibel as Senior Vice President of Strategic Marketing

Senior executive brings experience commercializing products in the molecular pathology and cancer markets at Roche Diagnostics, Life Technologies, Gen-Probe, and Sequenom

BILLERICA, Mass.--(BUSINESS WIRE)--RainDance Technologies, Inc., a genomics tools company simplifying the analysis of complex genetic diseases, today announced the appointment of Frederick (Fritz) L. Eibel as its new Senior Vice President of Strategic Marketing.

"We have the team, the products and a roadmap to address an expanding genomics marketplace."
Mr. Eibel brings more than two and a half decades of broad-based in vitro diagnostics (IVD) and life science experience focused primarily on new and emerging growth opportunities. He most recently served as Head of Genetic Analysis Commercial Operations at Agena Bioscience, which was previously the Genetic Analysis Division of Sequenom, Inc. Mr. Eibel was involved with the sale and integration of the division to Telegraph Hill Partners. Prior to his time at Sequenom and Agena, he held similar leadership positions at Gen-Probe Inc., Life Technologies Inc., and Roche Diagnostics Corp. Mr. Eibel also serves on the Board for MolecularMD, a molecular diagnostics company that provides custom companion diagnostic solutions and supporting clinical trial services for targeted cancer therapies.

"Fritz brings proven strategies for successfully marketing and selling products in today's academic and translational research communities, as well as industrial and applied markets. His extensive background and knowledge of our customers and collaborators will serve us well in the next phase of our company's success," said Roopom Banerjee, President and CEO of RainDance Technologies. "We have the team, the products and a roadmap to address an expanding genomics marketplace."

"The RainDance team has developed novel applications that we believe will change the way laboratories detect, monitor and analyze cancer, as well as other complex inherited or infectious diseases," said Mr. Eibel. "We believe that non-invasive fluid biopsy applications are the future of disease research and that RainDance is positioned for long-term success with its proven digital droplet technology platform enabling research investigators to gain valuable genomics information from a simple blood draw. This application has the potential to transform the detection of cancer."

Complex Genetics Made Simple

RainDance Technologies enables research with an innovative product portfolio to study cell-free and cell-based biomarkers for hereditary risk predisposition, initial detection, pathology, and residual disease. The company's products include:

RainDrop® System: Ultra-sensitive digital PCR system for research of early detection and monitoring of biomarkers for cancers, viruses, pathogens, and immune disorders.
ThunderBolts™ Cancer Panel: Next-Generation Sequencing (NGS) panel enabling highly sensitive, rapid, low input, and primary tumor profiling research in fresh biopsy, plasma and FFPE samples.
ThunderStorm® System: High-throughput, fully automated NGS content enrichment solution enabling researchers to generate what we believe to be the best-in-class data on large-scale disease panels, while delivering affordable workflow for high-volume studies.
About RainDance Technologies

RainDance Technologies is making complex genetics simple. The company's ultra-sensitive genomic tools enable research of novel non-invasive Fluid Biopsy™ applications that should result in more accurate, reliable, cost-effective, and early detection of cancer and inherited and infectious diseases. Major research institutions and laboratories around the world rely on the performance of RainDance systems. Based in Billerica, Massachusetts, the company supports customers using RainDrop Digital PCR and ThunderStorm Next-Generation Sequencing Content Enrichment Systems through its international sales and service operations as well as a global network of distributors and commercial service providers. For more information, please visit www.RainDanceTech.com.

The RainDance products are for Research Use Only; not for use in diagnostic procedures.

RainDance Technologies, the RainDance Technologies logo, RainDrop, ThunderStorm, ThunderBolts, and RainStorm are trademarks of RainDance Technologies, Inc. All other brands may be trademarks of their respective holders.


Media Contacts:
BlueChair Group
Pamela Mahoney, 408-674-6997
[email protected]

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Harvard scientists showed that a three-gene cocktail, by epigenetic reprogramming, could reverse the aging clock in mice retina nerve cells.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.